Atreca Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BCEL Nasdaq 8731 http://www.atreca.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atreca Inc

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update - Mar 29th, 2023 8:05 pm
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023 - Mar 23rd, 2023 9:00 pm
Atreca to Participate at Cowen’s 43rd Annual Health Care Conference - Mar 1st, 2023 1:00 pm
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target - Feb 6th, 2023 1:00 pm
We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate - Jan 19th, 2023 12:19 pm
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer - Jan 9th, 2023 1:30 pm
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update - Nov 10th, 2022 9:30 pm
Atreca to Present at Upcoming Investor Conferences - Nov 7th, 2022 9:30 pm
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting - Oct 5th, 2022 8:05 pm
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments - Aug 8th, 2022 8:05 pm
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer - Jun 16th, 2022 8:05 pm
Atreca Announces Corporate Reorganization to Extend Cash Runway - Jun 1st, 2022 8:01 pm
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments - May 11th, 2022 12:00 pm
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101” - May 4th, 2022 8:30 pm
Atreca to Present at Upcoming Virtual Investor Conferences - Apr 8th, 2022 8:05 pm
HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks - Apr 6th, 2022 1:26 pm
Atreca Announces Expansion of Preclinical Pipeline - Apr 5th, 2022 8:01 pm